

# Cellmid Ltd

11:34 03 Oct 2017

## Cellmid gets tax incentive for melanoma, hair growth research programs

Cellmid Limited (ASX:CDY) has received \$947,000 from the Australian Taxation Office under the Research and Development Tax Incentive Scheme for the 2017 financial year.

The tax credit relates to research and development expenditure incurred by Cellmid in relation to its midkine and FGF5 inhibitor programs.

Cellmid's midkine technology recently received scientific endorsement with a publication in the scientific journal Nature, confirming midkine's crucial role in the metastasis of aggressive melanoma.

The company's pre-clinical validation programs for midkine are also continuing in animal models of chronic kidney disease and systemic complications.

Cellmid's novel FGF5 inhibitor hair growth products are sold as over-the-counter, non-prescription natural medicines and cosmetics.

The company recently completed the first consumer experience study using the FGF5 inhibitor based evolis® Professional product range.

Significantly, 98% of consumers recorded new hair growth and 97% reported decreased hair fall by using evolis® over 120 days.

The consumer study results are critical for the company's U.S. premium retail strategy, and the data will be the key resource for the underlying marketing and public relations activities.

Cellmid is continuing to grow revenues from its consumer health division, through the wholly-owned subsidiary Advangen, which sells hair growth products.

Find out more from Maria Halasz at Proactive's CEO Sessions.  
Click below to register

- Melbourne: Wednesday 4th October.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 [action@proactiveinvestors.com.au](mailto:action@proactiveinvestors.com.au)

### No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that

**Price:** A\$0.5

**Market Cap:** A\$28.46M

### 1 Year Share Price Graph



### Share Information

**Code:** CDY

**Listing:** ASX

**52 week High Low**  
0.8p 0.35p

**Sector:** Pharma & Biotech

**Website:** [www.cellmid.com.au](http://www.cellmid.com.au)

### Company Synopsis:

Cellmid Ltd (ASX:CDY) is listed on the Australian Securities Exchange.

### Author:

**Proactive Investors Australia**

**+61 (0)2 9280 0700**

[action@proactiveinvestors.com.au](mailto:action@proactiveinvestors.com.au)

neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek personal advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.